Slayback Pharma

About Slayback Pharma

Slayback Pharma, established in 2011, operates as a specialty pharmaceutical company focused on the research, development, and manufacturing of complex generic and specialty drugs. The company's business model centers on identifying and developing difficult-to-formulate products, specifically targeting complex injectables and other non-solid oral dosage forms. This strategy involves a network of contract R&D laboratories and manufacturing organizations, enabling rapid development and leveraging sophisticated drug delivery technologies. Slayback's revenue is generated through the commercialization of its pharmaceutical products in both retail and hospital channels.

The company was founded by Ajay K Singh, who serves as the President and CEO. Singh's background includes an MBA from IIM Bangalore and an LLB from Delhi University. His career in the pharmaceutical industry began at Dr. Reddy's Laboratories, where he spent a decade in various roles, including Vice President of Strategy, Portfolio and Business Development for the North American Generics Division. This experience in product strategy, M&A, and intellectual property litigation directly informed Slayback's focus on complex generic opportunities. In 2018, Singh was recognized with the Ernst and Young Entrepreneur of the Year award in the Life Sciences category in New Jersey.

Slayback Pharma has achieved several key milestones. The company gained significant attention in 2016 with a $60 million Series A funding round from KKR. This was followed by a $50 million Series B investment from Everstone Capital in January 2020. The company began commercially selling its own products in the U.S. market in 2019. It has received multiple Abbreviated New Drug Application (ANDA) approvals from the FDA for products such as Icatibant Injection, a generic equivalent of Firazyr®, and Dexmedetomidine Hydrochloride Injection. In September 2023, Slayback Pharma was acquired by Azurity Pharmaceuticals and now operates as a wholly-owned subsidiary, combining Slayback's R&D capabilities with Azurity's commercial expertise.